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Abstract
Background: The application and better understanding of traditional and new breast tumor biomarkers and
prognostic factors are increasing due to the fact that they are able to identify individuals at high risk of breast
cancer, who may benefit from preventive interventions. Also, biomarkers can make possible for physicians to design
an individualized treatment for each patient. Previous studies showed that trace elements (TEs) determined by X-
Ray Fluorescence (XRF) techniques are found in significantly higher concentrations in neoplastic breast tissues
(malignant and benign) when compared with normal tissues. The aim of this work was to evaluate the potential of
TEs, determined by the use of the Energy Dispersive X-Ray Fluorescence (EDXRF) technique, as biomarkers and
prognostic factors in breast cancer.
Methods: By using EDXRF, we determined Ca, Fe, Cu, and Zn trace elements concentrations in 106 samples of
normal and breast cancer tissues. Cut-off values for each TE were determined through Receiver Operating
Characteristic (ROC) analysis from the TEs distributions. These values were used to set the positive or negative
expression. This expression was subsequently correlated with clinical prognostic factors through Fisher’s exact test
and chi-square test. Kaplan Meier survival curves were also evaluated to assess the effect of the expression of TEs in
the overall patient survival.
Results: Concentrations of TEs are higher in neoplastic tissues (malignant and benign) when compared with normal
tissues. Results from ROC analysis showed that TEs can be considered a tumor biomarker because, after establishing
a cut-off value, it was possible to classify different tissues as normal or neoplastic, as well as different types of
cancer.
The expression of TEs was found statistically correlated with age and menstrual status. The survival curves estimated
by the Kaplan-Meier method showed that patients with positive expression for Cu presented a poor overall survival
(p< 0.001).
Conclusions: This study suggests that TEs expression has a great potential of application as a tumor biomarker,
once it was revealed to be an effective tool to distinguish different types of breast tissues and to identify the
difference between malignant and benign tumors. The expressions of all TEs were found statistically correlated with
well-known prognostic factors for breast cancer. The element copper also showed statistical correlation with overall
survival.
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Background
Today, diagnosis and therapeutic approach for breast
cancer is based on predictive and prognostic factors
which are well-established for this disease. Prognostic
factors such as tumor size, lymph nodal status, TNM
staging information, histological grade and type, mitotic
figure counts and hormone receptor status have proven
to be of prognostic importance and useful in clinical
patient management [1]. Other prognostic factors have
been extensively studied biologically and clinically, but
their importance remains to be validated in statistically
robust studies, including c-erbB-2 (Her2-neu) [2], VEGF
[3], p53 expression [4], among others [1]. The combin-
ation of two or more parameters in order to define the
prognosis of the disease can be of considerable import-
ance, since it makes it possible to define the risk and to
indicate the potential value or not of a certain treatment
[5].
Several prognostic and predictive factors can act as
tumor biomarkers, depending on the given treatment.
Biomarkers are any type of measurable element which is
able to demonstrate the presence of malignancy or ma-
lignant potential, or to predict the behaviour of the
tumor, the prognosis or the treatment response [6]. A
better understanding and application of traditional
tumor biomarkers and the identification of new markers
is essential since they improve the patients quality of life
by sparing them from going under toxic treatments that
are unlikely to benefit them, and also by making it pos-
sible to establish an appropriate individualized treatment
for each type of tumor, avoiding unnecessary treatment
[5,6].
In recent years, the analysis of trace elements in
human tissues has gained great interest due to the role
that these elements play in biochemical and physiological
processes. Although trace elements constitute a minor
part of living tissues, they are important for vital pro-
cesses [7]. Some metals, usually present in proteins,
enzymes and cellular membranes, are essential for the
normal physiological function [8-10]. However, when in
abnormal expression, they seem to contribute in several
pathological processes, including tumor growth, invasion
and metastasis [11-13]. Individually, these elements seem
to contribute to various pathological processes, although
all the roles of these metals in carcinogenesis are still un-
known [14-20]. Previous publications of our group high-
lighted the study of some elements, such as calcium,
iron, copper and zinc, by determining the concentrations
of these elements in breast tissue by X-Ray Fluorescence
(XRF) techniques [7,21-23]. These studies showed, in
agreement with others [7,21,22,24-30], that these trace
elements are found in significantly higher concentrations
in neoplastic breast tissues (malignant and benign) when
compared to normal tissues.
X-Ray Fluorescence (XRF) is a representative multiele-
ment technique for the analysis of trace elements
[7,21,22,28,30-43]. This technique is based on exciting
the atoms in a material by applying an X-ray beam with
appropriate energy and subsequent detection of the char-
acteristic radiation emitted, which in turn is proportional
to the concentration of atoms in the material [44]. XRF
has many advantages, such as a simple and rapid proced-
ure of analysis in a large number of samples, high sensi-
tivity and low detection limits, enabling the
determination of elements concentrations in trace and
ultra-trace levels [45,46]. The XRF technique has some
variations depending on, among others, excitation and
detection setup [46]. Basically, if excitation is performed
under small angles relative to the sample, the technique
is called Total Reflection X-Ray Fluorescence (TXRF), if
incident beam is too small (order of microns), the tech-
nique is called Micro-X Ray Fluorescence (μ-XRF). If de-
tection is performed in terms of wavelength or energy of
radiation, the technique is called Wavelength Dispersive
X-Ray Fluorescence (WDXRF) or Energy Dispersive X-
Ray Fluorescence (EDXRF), respectively [46].
Therefore, the aim of this study was to evaluate the po-
tential of trace elements as biomarkers and evaluate their
prognostic value through EDXRF. To our knowledge,
this is the first study to evaluate the potential of trace
elements determined by X-ray fluorescence techniques
as biomarkers and prognostic factors in breast cancer.
Methods
Patients
A total of 81 patients with normal, malignant and benign
breast tissues diagnosed between 2003 and 2006 were
randomly chosen from the files of the Department of
Pathology of Ribeirão Preto Medical School in the Uni-
versity of São Paulo, at the Ribeirão Preto General
Teaching Hospital (HCFMRP/USP). Clinical data and
important prognostic information, such as age, men-
strual status, tumor size, histological grade, staging,
lymph node involvement, estrogen and progesterone
receptors and HER-2 status were obtained from 59 avail-
able medical records. The study was approved by the
local ethics committee (Research Ethics Committee of
HCRP and FMRP-USP - Process 4308/2009) and fol-
lowed the ethical guidelines of 1975 Helsinki
Declaration.
Breast tissue samples
Breast tissue samples were provided by the Department
of Pathology at HCFMRP/USP. The collected material
was residual tissue obtained from routine surgical proce-
dures of mastectomy and mastoplasty. Pathological in-
formation was available for all samples. After surgery,
samples were stored in formalin 10% until analysis. The
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patients were selected randomly to represent different
aspects of breast tissues. The casuistic consisted of 38
samples of normal breast tissues (used as control group),
9 benign tumors (fibroadenoma) and 34 samples of ma-
lignant tumors (both in situ and infiltrating ductal car-
cinomas). In 25 of these 34 samples of malignant
tumors, normal adjacent tissues were taken 2 cm away
from tumors.
To perform XRF measurements, each sample was cut
in 1 cm-thick and 1 cm-long sections, and placed in a
specific sample holder, covered by KaptonW film, widely
used in XRF experiments.
X-ray fluorescence measurements
Energy Dispersive X-Ray Fluorescence (EDXRF) experi-
ments were performed at the Laboratory of Radiation
Physics and Dosimetry, at the University of São Paulo
(USP/Ribeirão Preto). A beam with energy of 17.44 keV
emitted from an X-ray tube coupled with a graphite
monochromator was used to excite simultaneously sev-
eral trace elements in breast tissues. Samples were placed
at a 45 ° angle to the incident beam in order to minimize
attenuation effects [45]. For each sample, three datasets
were collected from different regions of the sample to re-
duce the influence of a possible sample inhomogeneity.
The acquisition time was fixed at 1000 s, maintaining
the statistical uncertainty below 4%. Fluorescent signals
emitted from trace elements were detected with a semi-
conductor detector Si(Li) (energy resolution of 165 eV at
5.89 keV), and placed at a 90 ° angle to the incident
beam. Figure 1 shows a typical spectrum of EDXRF for a
benign breast sample. One can observe the presence of
several elements such as Ca, Fe, Cu and Zn. Trace ele-
ments concentrations were quantified by the external
standard method associated with the scattered intensity
method [7,45]. Detection limits were determined and the
values range was between 0.2 mg.kg-1 (for heavier ele-
ments such as Zn) and 3.5 mg.kg−1 (for lighter elements
such as Ca). A reference material (IAEA-V10) [47] with
certified concentrations of several trace elements was
used to test the method accuracy. Results revealed that
differences between certified and obtained values were
lower than 7% for all elements analyzed in the reference
material, validating the quantification procedure.
Receiver operating characteristics (ROC) analysis
In order to obtain decision threshold values (cut-off
values) for each trace element, ROC curve analysis was
employed [48]. The gold standard was based on histo-
logical diagnosis made by an experienced breast patholo-
gist (ARS). ROC curves were generated based on
concentration data of two types of tissues at a time.
Table 1 summarizes the groups of tissues analyzed.
The cut-off values for the concentration of trace ele-
ments chosen in this work corresponded to the point
where the sensitivity and specificity were simultaneously
higher [49,50]. Based on the cut-off value for each elem-
ent, all trace elements concentration values were dichot-
omized in 0 or 1 (without or with tumor, respectively),
transforming the distribution of the trace elements con-
centrations in a discrete variable (trace element
expression).
Evaluation of trace elements as tumor biomarker
The area under the ROC curve summarizes the perform-
ance of the test and the higher the discriminatory ability
of the test, the more the area under the curve
approaches to 1 [48]. In this work, the accuracy was con-
sidered excellent when the area under the curve was
equal to or greater than 0.8 [26,50].
Evaluation of trace elements as prognostic factors
Trace element expression (positive, 1, or negative, 0) was
correlated with clinicopathological data using the Fisher’s
exact test in the case of 2 variables and the chi-square
test for three or more variables. The prognostic factors
assessed were age, menstrual status, tumor size, histo-
logical grade, staging, lymph node involvement, estrogen
Figure 1 Typical EDXRF breast cancer spectrum.
Table 1 Groups of tissues evaluated by ROC curve
analysis
Group analyzed Tissue established
as disease present
Tissue established
as disease absent
Group 1 (paired samples) Malignant Normal Adjacent
Group 2 Malignant Normal
Group 3 Benign Normal
Group 4 Benign Malignant
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and progesterone receptors, and also HER-2 status. The
categorization of each prognostic factor was based on
previous works described in the literature [51,52]. Cor-
relation between trace elements and tumor size was per-
formed only for malignant and benign breast tissues.
Correlation between trace elements and histological
grade, TNM staging, and lymph node status was con-
ducted only for malignant tissues.
Survival curves
The survival curves estimated by the Kaplan-Meier
method were applied to study the isolated effect of trace
element expression on the prognosis and to describe the
cumulative proportions of deaths (overall survival) of
patients [53]. These curves were built based on the ex-
pression of trace elements as independent variables and
overall survival as the dependent variable. The time of
diagnosis was considered the initial date and the event
or failure was considered the occurrence of death. In this
study, all cases of death were due to the presence of
breast cancer. The cases that were not followed up until
Table 3 Trace elements concentrations data in different
tissues based on some descriptive parameters
Element Normal Normal
Adjacent
Malignant Benign
Calcium
Mean 130.7 283.1 668.9 1770.3
Median 105.7 225.2 635.2 1320.3
Range 16.1–483.2 19.6–722.8 62.7–3572.5 300.9–4040.8
1st and 3rd
quartile
68.9/186.6 154.5/342.0 271.0/793.8 795.5/2734.9
Iron
Mean 15.6 15.8 33.0 15.1
Median 11.8 11.4 21.0 15.3
Range 3.6–87.9 4.9–103.4 8.7–166.9 5.5–26.6
1st and 3rd
quartile
6.4/20.2 7.3/16.0 12.8/42.6 11.2/18.7
Copper
Mean 3.3 0.6 1.0 2.1
Median 0.4 0.5 0.7 1.6
Range 0.1–103.0 0.1–1.7 0.2–5.4 0.9–6.7
1st and 3rd
quartile
0.2/0.7 0.3/0.9 0.5/1.3 1.7/1.9
Zinc
Mean 2.1 2.8 7.1 12.2
Median 1.5 2.3 6.6 11.1
Range 0.1–9.7 0.3–8.8 1.6–30.0 4.5–21.1
1st and 3rd quartile 0.4/3.2 1.7/3.5 3.9/8.4 6.9/15.5
First and third quartiles correspond to the 25th and 75th percentiles
respectively. All values are in mg/kg.
Table 2 Clinicopathological characteristics of patients
Normal
tissues
Malignant
tissues
Benign
tissues
Age (years)
≤ 30 2 0 4
30–50 14 14 5
50–70 2 9 1
≥ 70 1 8 0
Menstrual status
Premenopausal 17 15 7
Postmenopausal 2 16 3
Tumor size (cm)
≤ 2 − 4 1
2–5 − 20 7
≥ 5 − 7 1
Histologic Grading
(Bloom and
Richardson)
G1 − 6 −
G 2 − 12 −
G 3 − 8 −
Pathologic staging
I − 0 −
II − 10 −
III − 9 −
IV − 1 −
Lymph nodes
Negative − 11 −
1–3 – 4 –
≥ 3 – 15 –
Death
Yes 0 10 0
No 19 21 9
Estrogen receptor
Negative – 12 –
Positive – 21 –
Progesterone
receptor
Negative – 13 –
Positive – 20 –
HER2
0 – 12 –
1+ – 7 –
2+ – 8 –
3+ – 6 –
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death were censored according to the Kaplan-Meier
method [54]. The results were then compared using the
log-rank test in order to determine statistically signifi-
cant differences between the obtained curves. Statistical
significance was based on confidence intervals of 95%.
The statistical analyses of data were performed using
the Software SPSSW 13.0.
Results and discussion
Patients
In a total of 81 patients, 46.9% were diagnosed with nor-
mal breast tissue, 41.9% with malignant tumor and 11.2%
with benign tumor. All patients were women, with a
mean age of 50 years (range, 17 to 88 years of age). The
mean size of the tumors was of 3.6 cm (range, 0.5 to
Figure 2 ROC curves obtained from the study of trace element concentration distributions. Group 1: malignant and normal adjacent,
group 2: malignant and normal, group 3: benign and normal, group 4: benign and malignant. Reference lines are shown in dotted lines.
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15 cm). Clinical features obtained from available medical
records are reported in Table 2, according to tissue type.
Trace elements concentrations
Trace elements concentrations data, determined by
EDXRF, based on descriptive parameters (range, median,
lower quartile, and upper quartile) are shown in Table 3.
From this table it is possible to note that trace elements
distributions are large, a common feature in biological
parameters [55]. These variations in concentration may
result from several factors, such as differences in diet,
age, genetics and especially due to different disease
stages [7,34,56]. Data in Table 3 also show that concen-
trations of trace elements are higher in neoplastic tis-
sues (malignant and benign) than in normal tissues.
Although the role of trace elements has not yet been
well established in literature, the increase in tumor tis-
sues may be related to metabolic and structural aspects
[17,29,57-60], which indicates its potential as a tumor
biomarker.
Table 3 also shows that, except for Fe, all elements
concentrations are higher in benign tumors than in ma-
lignant tumors. This finding is in agreement with other
authors [7,21,27,30,33,34] and may be associated with
structural [59,61,62] and metabolic aspects [18,19,63-67]
as well as tumor development [68,69].
Cut-off determination
Figure 2 shows the ROC curves obtained for all elements
studied in this work, comparing different types of tissues.
In the same way that areas under the ROC curves pro-
vided a measure of accuracy of the test (diagnostic), the
coordinates of sensitivity and specificity are also import-
ant because they provide information to assist in the de-
cision of the cut-off value used to determine the
outcome of the trial. Table 4 describes the sensitivity and
specificity associated with the cut-off value chosen, as
well as the values of the areas under the curves and the
asymptotic significance in area determination. The cut-
off limits were selected based on the highest sum of sen-
sitivity and specificity [49].
Trace elements as tumor biomarkers and prognostic
factors
From Table 4 it is possible to observe that for each test,
some elements (highlight by *) show the area under the
ROC curve higher than 0.8. Concentrations distribution
of these elements and respective cut-off values are
shown in Figure 3 through box plot graphs, which
makes it possible to represent the distribution of con-
centrations of trace elements based on descriptive para-
meters such as range, median and quartile range [70].
From Figure 3 (a) it is possible to identify that the cut-
off values for the elements Fe and Zn are used to clas-
sify normal adjacent and malignant tissues with high
sensitivity and specificity (values on Table 4). Figures 3
(b), 3(c) and 3(d) illustrate the distributions of concen-
trations and their respective cut-off values for other
trace elements which made it possible to classify other
groups of breast tissues. It is also observed in Table 4
that all trace elements may be considered as tumor bio-
markers once they show areas under ROC curve near
0.8. However, these elements could distinguish breast
tumors with a lower accuracy.
The assigned value to each variable (0 or 1), based on
the cut-off value, allowed us to assess the expression of
trace elements, and correlate them with clinicopathologi-
cal data, with the results shown in Table 5. In this table,
it is possible to note that the expression of all trace ele-
ments is correlated with the type of tissue. These find-
ings emphasize that there is a possibility of using these
elements as tumor biomarkers.
Table 5 also shows that the trace elements expression
is statistically correlated with age and menstrual status.
Table 4 ROC graphs parameters obtained for trace
elements present in different tissues
Group 1: Malignant (1) and normal adjacent tissues
(0)-paired samples
Element Best cut-
off
(mg.kg-1)
Sensitivity
(%)
Specificity
(%)
Area under
ROC
curve
p
Ca 580.9 55.2 93.1 0.757 0.001
Fe* 19.3 69.0 93.1 0.837 <0.001
Cu 1.0 55.2 82.8 0.740 0.002
Zn* 4.0 72.4 82.8 0.824 <0.001
Group 2: Malignant (1) and normal tissues (0)
Ca* 212.6 70.7 86.4 0.838 <0.001
Fe 12.6 78.0 63.6 0.743 <0.001
Cu 0.8 53.7 81.8 0.707 0.001
Zn* 3.4 75.6 86.4 0.874 <0.001
Group 3: Benign (1) and normal tissues (0)
Ca* 288.8 100.0 93.2 0.992 <0.001
Fe 12.8 66.7 63.6 0.616 0.276
Cu* 0.9 100.0 86.3 0.947 <0.001
Zn* 4.4 100.0 93.1 0.985 <0.001
Group 4: Benign (1) and malignant tissues (0)/Δ Benign (0)
and malignant tissues(1)
Ca* 794.6 77.8 80.5 0.816 0.003
Fe Δ 20.7 48.7 88.8 0.675 0.103
Cu* 0.9 100.0 56.1 0.808 0.004
Zn 4.4 100.0 46.3 0.759 0.016
The values 1 and 0 used in graphs construction represent tissues considered
with presence and absence of disease, respectively. Elements highlight by *
show area under the ROC curve higher than 0.8.
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Regarding the menstrual status of the patients, our
results indicate that most post-menopause women have
a positive correlation with the expression of trace ele-
ments. There were no statistically significant correlations
for the other factors evaluated. However, the number of
patients in each group of prognostic factors may have
been too small to detect a statistically significant correl-
ation. Furthermore, since prognostic factors evaluated in
Table 5 are independent [1,2,51,71-75], the correlation
with the tissue type, age and menopausal status suggests
that expression of trace elements may be considered a
prognostic factor.
Survival curves estimated by the Kaplan-Meier
method, used to examine the expression of trace ele-
ments as a function of overall survival of patients diag-
nosed with malignant tumors, and the values of the log-
rank tests are presented in Figure 4. Figure 4 (a) shows
that patients with positive expression for Cu presented a
poor overall survival (p< 0.001). Indeed, studies report
that copper has a crucial role in the angiogenic mechan-
ism, and tumors that become angiogenic exhibit a high
metastatic potential, a major cause of mortality in
patients with breast cancer [18,76]. In addition, in order
to confirm this hypothesis, it would be interesting in fu-
ture studies to examine the presence of angiogenic ves-
sels in these cases.
Even without showing statistically significant difference
for the other elements, the graphs in Figures 4(b) and 4
(c) indicate that the positive expression for Fe and Zn is
associated with an increased risk of death. Data in
Figure 4b show that there were no deaths among patients
with negative expression for Fe, thus the overall survival
Figure 3 Box plots of trace elements in different breast tissues. (a) normal adjacent and malignant (b) normal and malignant (c) normal and
benign and (d) malignant and benign. The circles indicate outliers, which are values between 1.5 and 3 times the inter quartile ranges. Color
dotted lines represent the cut-off values for each correspondent color distribution.
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did not need to be recalculated at any time and only cen-
sored data are presented.
Calcium (Figure 4 (d)) presents an opposite trend. This
opposite association of calcium with poor survival can be
associated with the presence of microcalcifications in tis-
sue, once differences in the structures of microcalcifica-
tions may be inversely associated with the degree of
malignancy [14,61,62].
The results of this work revealed that the concentra-
tions of trace elements, determined by EDXRF, are im-
portant objects of study to be established as prognostic
factors in the near future, since the larger the number of
biomarkers, the higher the number of possible combina-
tions that can help the physician to establish the appro-
priate therapy for each case, providing a more
individualized therapeutic management and improving
the selection of patients for adjuvant therapy.
Conclusions
In this work, Energy Dispersive X-Ray Fluorescence
technique was employed to determine Ca, Fe, Cu, and
Zn concentrations in normal and neoplastic breast tis-
sues. Cut-off values, obtained by ROC analysis, allowed
us to distinguish different types of breast tissues, includ-
ing malignant and benign. In addition, the correlations
between trace elements expression and tissue type sug-
gest that trace elements can be used as tumor
biomarkers.
The prognostic value of the trace elements was
demonstrated through the correlation between their
Table 5 Correlation between trace elements expression,
tissue type and prognostic factors
Calcium
status
Iron
status
Copper
status
Zinc
status
− + − + − + − +
Breast Tissue
Normal 33 5 22 16 29 9 31 7
Malignant 7 27 6 28 17 17 7 27
Benign 0 9 3 6 0 9 0 9
Normal Adjacent 11 14 13 12 16 9 17 8
p <0.001 0.005 <0.001 <0.001
Age (years)
< 30 0 6 4 2 0 6 0 6
30–50 17 16 11 22 22 11 17 16
50–70 3 9 2 10 6 6 4 8
> 70 1 8 0 9 4 5 0 9
p 0.019 0.028 0.023 0.007
Menstrual status
Premenopausal 17 22 17 22 26 13 17 22
Postmenopausal 4 17 0 21 6 15 4 17
p 0.050 <0.001 0.005 0.05
Death
Yes 17 33 17 33 30 20 19 31
No 4 6 0 10 2 8 2 8
p 0.490 0.025 0.024 0.239
Tumor size (cm)
≤ 2 1 4 1 4 2 3 1 4
2–5 5 22 5 22 10 17 5 22
≤ 5 1 7 2 6 4 4 1 7
p 0.914 0.922 0.806 0.914
Histologic Grading
(Bloom and Richardson)
G1 1 5 1 5 5 1 2 4
G 2 1 11 0 12 5 7 1 11
G 3 3 5 2 6 5 3 4 4
p 0.264 0.208 0.228 0.111
Pathologic staging
II 4 6 1 9 3 7 4 6
III 3 6 2 7 3 6 2 7
IV 0 1 0 1 0 1 1 0
p 0.719 0.69 0.788 0.271
Lymph nodes
Negative 2 9 2 9 8 3 2 9
1–3 0 4 0 4 2 2 0 4
≥ 3 5 10 3 12 6 9 5 10
p 0.330 0.626 0.253 0.33
Table 5 Correlation between trace elements expression,
tissue type and prognostic factors (Continued)
Estrogen receptor
Negative 3 9 2 10 6 6 2 10
Positive 5 16 3 18 12 9 6 15
p 0.627 0.612 0.486 0.373
Progesterone receptor
Negative 2 11 2 11 7 6 2 11
Positive 6 14 3 17 11 9 6 14
p 0.299 0.669 0.614 0.299
HER2
score 0 3 9 3 9 10 2 5 7
score 1+ 2 5 0 7 3 4 1 6
score 2+ 1 7 0 8 2 6 1 7
score 3+ 2 4 2 4 3 3 1 5
p 0.814 0.163 0.064 0.369
(−) and (+) represents negative and positive expression respectively. The
values of significance for Fisher and chi-square tests are represented by p.
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expression and parameters such as age and menstrual
status. Moreover, patients with positive copper expres-
sion showed a poorer survival. The greater the number
of prognostic factors, the greater the number of possible
combinations that can help doctors identify patients with
very aggressive tumors and institute appropriate therapy
for each case. In addition, doctors may also consider the
effectiveness of different treatment alternatives and the
cost-benefit to the patient.
The results in this work suggest that the expression of
trace elements is a clinically relevant potential tool that
could be integrated in decision-making, making it pos-
sible to individualize the treatment and to develop target
therapies based on trace elements expression.
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